ep top consensu ep beat
better revenu profit factor line
ad boost ep guidanc
primarili us tax reform rais ep
reflect lower partial off-set
weaker contribut pharmedium tp move
higher view
revenu profit exceed plan revenu growth vs estimate
driven stronger experi across core distribut
despit suspens product pharmedium facil
revenu rose healthi vs estimate repres
profit key compon posit thesi gross margin
bp line oper expens bp slightli better
plan drive ebitda margin deterior bp bp plan
segment oper profit distribut improv better plan
flow million help facilit million share repurchas
pharmedium conundrum mask improv core distribut
hearten ep upsid stronger distribut perform
challeng pharmedium modestli taint better underli trend
drug price encouragingli re-affirmed brand inflat gener
deflat expect character stabil environ
posit rhetor view pharmedium halt product
largest facil follow inspect novemb produc
document relat associ subpoena disclosur
facil remain close still sever posit quarter
hope lost manag confid pharmedium lt
fundament see revenu profit driver wba matur
esrx relationship contribut diversifi non-cor unit risk
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
global pharmaceut sourc
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
price feb rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
similar
low end
competit less price
variabl last year
competit less price
competit less price
buysid in-lin expect
slightli msd full-year
higher end
flat mid-singl digit
compani mention price
